{'fraction_non_alphanumeric': 0.02556610664718773, 'fraction_numerical': 0.019722425127830533, 'mean_word_length': 5.061946902654867, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
All you need to read in the other general journals

People on maintenance haemodialysis have a high risk of cardiovascular events and the search is on for a safe way to protect them from this lethal companion to end stage renal disease. Statins now join the long list of interventions that have fallen by the wayside, after rosuvastatin failed to protect patients from heart attacks, strokes, or death from cardiovascular disease in a placebo controlled trial (hazard ratio for rosuvastatin v placebo 0.96, 95% CI 0.84 to 1.11). All participants were over 50. About a quarter had diabetes, and about 40% had pre-existing cardiovascular disease. Rosuvastatin worked no better than a placebo for anyone, although it reduced serum concentrations of low density lipoprotein cholesterol by a mean of 43% from a baseline of 2.6 mmol/l. The trial was large (n=2776) and just powerful enough to exclude a clinically meaningful effect, says an editorial (p 1455). The most likely explanation for the disappointing results is that statins simply don’t work in these patients—probably because their heart disease has an unusual aetiology that doesn’t respond to cholesterol lowering treatments. People on maintenance haemodialysis tend to have left ventricular hypertrophy and aortic calcification, rather than the atheromatous heart disease encountered in the general population.